
How those diabetes and weight loss drugs may be helping hearts
Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.
People: This is a study based on research using people.
People with diabetes who received a drug in the same group of diabetes/weight loss drugs as Ozempic - a glucagon-like peptide-1 receptor agonist (GLP-1 RA) called liraglutide - improved key markers of heart health, according to international and Australian research. The researchers found that, compared to another type of diabetes drug, those taking liraglutide for 16 weeks improved key measures of heart health. These measures are thought to point to potential ways that heart disease develops in type 2 diabetes. The researchers say the effects of liraglutide on these measures offer important insights into how these drugs might be having beneficial effects on heart disease as well as diabetes.
Journal/conference: Journal of the American College of Cardiology
Research: Paper
Organisation/s: Baker Heart and Diabetes Institute, Monash University, The University of Melbourne, University of Leeds, UK
Attachments:
Note: Not all attachments are visible to the general public
News for:
Australia
International
VIC
Media contact details for this story are only visible to registered journalists.